Author(s): Stenkvist J, Weiland O, Snnerborg A, Blaxhult A, Falconer K, Stenkvist J, Weiland O, Snnerborg A, Blaxhult A, Falconer K
Abstract Share this page
Abstract BACKGROUND: HCV co-infection is a leading cause of death in HIV-positive patients. Despite a strong indication for the treatment of HCV, treatment uptake is generally lower than in HCV mono-infected patients. The aim of this study was to determine the HCV treatment uptake and to define factors associated with initiation or deferral of HCV treatment in Swedish HIV/HCV co-infected patients. METHODS: All 5315 adult HIV-positive patients in Sweden are included in the InfCare HIV database. Demographic, virologic, and treatment data for 652 HIV/HCV co-infected patients were extracted from this database in September 2010. Factors associated with initiation of interferon-based HCV treatment were analysed. Patient- and physician-reported reasons for deferring HCV treatment were investigated in a subgroup. RESULTS: The anti-HCV prevalence was 14\% and the chronic HCV infection rate 11\%. In total, 25\% of HIV/HCV co-infected patients had initiated HCV treatment. HCV genotype 2 or 3, HIV transmission route other than intravenous drug use, and ongoing HIV treatment were factors associated with a higher HCV treatment rate. The main reason for not having initiated HCV treatment was intravenous drug use or alcohol abuse. CONCLUSIONS: The 14\% prevalence of anti-HCV noted in Swedish HIV-infected patients was low by international comparisons. The 25\% HCV treatment rate noted in our HIV/HCV co-infected patients was high and of the same magnitude as that published for HCV mono-infected patients in Sweden. People who inject drugs had the lowest HCV treatment uptake.
This article was published in Scand J Infect Dis
and referenced in Journal of AIDS & Clinical Research